218 related articles for article (PubMed ID: 12588472)
1. Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials.
Cremonini F; Delgado-Aros S; Camilleri M
Neurogastroenterol Motil; 2003 Feb; 15(1):79-86. PubMed ID: 12588472
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials.
Rahimi R; Nikfar S; Abdollahi M
Clin Ther; 2008 May; 30(5):884-901. PubMed ID: 18555935
[TBL] [Abstract][Full Text] [Related]
3. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome.
Camilleri M; Chey WY; Mayer EA; Northcutt AR; Heath A; Dukes GE; McSorley D; Mangel AM
Arch Intern Med; 2001 Jul; 161(14):1733-40. PubMed ID: 11485506
[TBL] [Abstract][Full Text] [Related]
4. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist.
Camilleri M; Mayer EA; Drossman DA; Heath A; Dukes GE; McSorley D; Kong S; Mangel AW; Northcutt AR
Aliment Pharmacol Ther; 1999 Sep; 13(9):1149-59. PubMed ID: 10468696
[TBL] [Abstract][Full Text] [Related]
5. A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS.
Krause R; Ameen V; Gordon SH; West M; Heath AT; Perschy T; Carter EG
Am J Gastroenterol; 2007 Aug; 102(8):1709-19. PubMed ID: 17509028
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial.
Camilleri M; Northcutt AR; Kong S; Dukes GE; McSorley D; Mangel AW
Lancet; 2000 Mar; 355(9209):1035-40. PubMed ID: 10744088
[TBL] [Abstract][Full Text] [Related]
7. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome.
Lembo T; Wright RA; Bagby B; Decker C; Gordon S; Jhingran P; Carter E;
Am J Gastroenterol; 2001 Sep; 96(9):2662-70. PubMed ID: 11569692
[TBL] [Abstract][Full Text] [Related]
8. Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials.
Andresen V; Montori VM; Keller J; West CP; Layer P; Camilleri M
Clin Gastroenterol Hepatol; 2008 May; 6(5):545-55. PubMed ID: 18242143
[TBL] [Abstract][Full Text] [Related]
9. Alosetron.
Balfour JA; Goa KL; Perry CM
Drugs; 2000 Mar; 59(3):511-8; discussion 519-20. PubMed ID: 10776833
[TBL] [Abstract][Full Text] [Related]
10. Effects of alosetron on gastrointestinal transit time and rectal sensation in patients with irritable bowel syndrome.
Thumshirn M; Coulie B; Camilleri M; Zinsmeister AR; Burton DD; Van Dyke C
Aliment Pharmacol Ther; 2000 Jul; 14(7):869-78. PubMed ID: 10886042
[TBL] [Abstract][Full Text] [Related]
11. Tolerability and safety of alosetron during long-term administration in female and male irritable bowel syndrome patients.
Wolfe SG; Chey WY; Washington MK; Harding J; Heath AT; McSorley DJ; Dukes GE; Hunt CM
Am J Gastroenterol; 2001 Mar; 96(3):803-11. PubMed ID: 11280555
[TBL] [Abstract][Full Text] [Related]
12. Review article: the safety and efficacy of alosetron, a 5-HT3 receptor antagonist, in female irritable bowel syndrome patients.
Mangel AW; Northcutt AR
Aliment Pharmacol Ther; 1999 May; 13 Suppl 2():77-82. PubMed ID: 10429745
[TBL] [Abstract][Full Text] [Related]
13. Effect of alosetron on left colonic motility in non-constipated patients with irritable bowel syndrome and healthy volunteers.
Clemens CH; Samsom M; Van Berge Henegouwen GP; Fabri M; Smout AJ
Aliment Pharmacol Ther; 2002 May; 16(5):993-1002. PubMed ID: 11966509
[TBL] [Abstract][Full Text] [Related]
14. Patient satisfaction with alosetron for the treatment of women with diarrhea-predominant irritable bowel syndrome.
Olden K; DeGarmo RG; Jhingran P; Bagby B; Decker C; Markowitz M; Carter E; Bobbitt W; Dahdul A; DeCastro E; Gringeri L; Johanson J; Levinson L; Mula G; Poleynard G; Stoltz RR; Truesdale R; Young D;
Am J Gastroenterol; 2002 Dec; 97(12):3139-46. PubMed ID: 12492201
[TBL] [Abstract][Full Text] [Related]
15. Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome.
Chey WD; Chey WY; Heath AT; Dukes GE; Carter EG; Northcutt A; Ameen VZ
Am J Gastroenterol; 2004 Nov; 99(11):2195-203. PubMed ID: 15555002
[TBL] [Abstract][Full Text] [Related]
16. Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers.
Houghton LA; Foster JM; Whorwell PJ
Aliment Pharmacol Ther; 2000 Jun; 14(6):775-82. PubMed ID: 10848662
[TBL] [Abstract][Full Text] [Related]
17. Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients.
Jones RH; Holtmann G; Rodrigo L; Ehsanullah RS; Crompton PM; Jacques LA; Mills JG
Aliment Pharmacol Ther; 1999 Nov; 13(11):1419-27. PubMed ID: 10571597
[TBL] [Abstract][Full Text] [Related]
18. A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome.
Bardhan KD; Bodemar G; Geldof H; Schütz E; Heath A; Mills JG; Jacques LA
Aliment Pharmacol Ther; 2000 Jan; 14(1):23-34. PubMed ID: 10632642
[TBL] [Abstract][Full Text] [Related]
19. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS.
Chang L; Ameen VZ; Dukes GE; McSorley DJ; Carter EG; Mayer EA
Am J Gastroenterol; 2005 Jan; 100(1):115-23. PubMed ID: 15654790
[TBL] [Abstract][Full Text] [Related]
20. Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: analysis of two controlled trials.
Lembo AJ; Olden KW; Ameen VZ; Gordon SL; Heath AT; Carter EG
Clin Gastroenterol Hepatol; 2004 Aug; 2(8):675-82. PubMed ID: 15290660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
